A
Allecra Therapeutics
Novel antibiotics to combat drug-resistant bacterial infections
About Allecra Therapeutics
Allecra Therapeutics is a clinical-stage biopharmaceutical company that develops therapies to combat antibiotic resistance in gram-negative bacteria.
The company's lead product, EXBLIFEP®, is a combination of enmetazobactam, a novel beta-lactamase inhibitor, and the cephalosporin cefepime. This combination is designed to be effective against multi-drug-resistant (MDR) gram-negative bacteria. The U.S. Food and Drug Administration (FDA) has approved EXBLIFEP® for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older. The company's business model is focused on the development and commercialization of this and other novel antibiotic treatments. Allecra Therapeutics operates in the biopharmaceutical market, specifically targeting infectious diseases and antibiotic resistance. The company collaborates with other pharmaceutical companies for the commercialization of its products in different regions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 62.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Infections and Infectious Diseases, Bacteria, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, radar de l'innovation, DT and LS, observatoire healthtech
- Business model
- Manufacturing
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2016 | $24M | $97M | Andera Partners · Nicholas Benedict · Forbion Capital Partners · EMBL Ventures | ↗ |
| SERIES AOther financing | Apr 2015 | $17M | $66M | EMBL Ventures · Andera Partners | — |
Growth signals
Latest recorded traffic for Allecra Therapeutics is 300 monthly website visits, down 84.2% over the last three months. Allecra Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Allecra Therapeutics in the Saint-Louis ecosystem
The Allecra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
EMBL Ventures
Andera Partners
Delos Capital
Nicholas Benedict
Forbion Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allecra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allecra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










